Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). An open, long-term, multicenter study in 5,635 patients.
Different therapies can be applied for the prevention of chronic bronchitis exacerbations: vaccinations, antibiotics, immunomodulating and mucoregulating drugs. Among the latter, ambroxol was tested in a multicenter open study in 5,635 outpatients during a 6-month winter period. The results achieved in a large and heterogeneous number of patients confirm the positive trend already observed in a multicenter double-blind study versus placebo in 214 patients. Particularly significant is the decrease in the number of exacerbations with time, above all in patients with more than 2-3 episodes. In parallel, the improvement in the clinical pattern, observed through the contemporaneous assessment of respiratory signs and symptoms and of the length of antibiotic therapy, confirms the soundness of the results achieved.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000551:Ambroxol / Q000009:adverse effects / Q000627:therapeutic use*; D001964:Bromhexine; D001991:Bronchitis / Q000517:prevention & control*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic
D000551:Ambroxol; D001964:Bromhexine